Compound ID | 1302
REDX08106
Class: Bacterial topoisomerase inhibitor
| Spectrum of activity: | Gram-negative |
| Details of activity: | The NBTI REDX08106 exhibits potent bactericidal activity against clinically relevant pathogens, which results from its ability to specifically inhibit bacterial type II topoisomerases. Potent antibacterial activity when used to treat A. baumannii-induced mouse thigh infection. |
| Institute where first reported: | Redx Pharma; Discuva Ltd; University of Bristol; Glaxosmithkline |
| Year first mentioned: | 2017 |
| Highest developmental phase: | Preclinical |
| Development status: | Active |
AntibioticDB is supported by GARDP.
If you have feedback, experience problems, or are interested in a collaboration, please contact us. | Terms and conditions
The content of this site is intended for educational and scientific research purposes only and not as a source of medical advice or consultation.